Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:activeIngredient |
elivaldogene autotemcel
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
not assigned
|
| gptkbp:brand |
gptkb:Skysona
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:developer |
gptkb:bluebird_bio
|
| gptkbp:genericName |
elivaldogene autotemcel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Skysona
|
| gptkbp:indication |
early active cerebral adrenoleukodystrophy
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gene addition therapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
infections
cancer risk delayed platelet engraftment graft versus host disease |
| gptkbp:usedFor |
cerebral adrenoleukodystrophy
|
| gptkbp:bfsParent |
gptkb:bluebird_bio
gptkb:Bluebird_Bio |
| gptkbp:bfsLayer |
7
|